BioTech Medics, Inc. Announces Significant Finding Treating Diabetic Patients

DALLAS, Nov. 10 /PRNewswire-FirstCall/ -- Charles R. Crane, MD, President & Medical Director of BioTech Medics, Inc., announced today a significant finding while treating neuropathic pain in diabetic patients with the NeuroLase (TM) therapeutic medical laser.

"Over 25 diabetic patients have been successfully treated with the Neurolase (TM) Medical Laser in Dallas over the past 2 years for painful diabetic peripheral neuropathy, using the BioTech L3aser(TM) proprietary Protocols. Most patients had previously been treated with narcotics, antidepressants and anticonvulsants without lasting improvement. Using the non-invasive, drug-free Neurolase (TM) Medical Laser these patients were able to achieve significant lasting pain relief. These patients were also experiencing problems with glucose control even with injections of insulin. Blood glucose levels in excess of 300 were not uncommon," said Dr. Crane. "In follow-up visits, we have discovered that within 24 hours of laser treatment, patients experienced a substantial decrease in blood sugar with glucose readings below 150 and predictable control. Decreased medication usage was also noted. Several of the patients who have had bi-weekly laser treatments for pain management over 6 months, consistently had blood sugar readings in the normal range."

BioTech Medics has sent a letter to the World Association of Laser Therapy (WALT) of which BTMD is a member, concerning this finding and is seeking medical research grants for a clinical study. There are over 18 million Americans who have diabetes, according to the ADA, with an estimated 5 million experiencing painful neuropathy.

BioTech Medics operates a Pain Management & Wellness Center in Dallas; is a distributor for the NeuroLase Therapeutic Medical Laser. The company plans on 100 or more centers nationwide.

Dr. Crane is a Texas and Tennessee licensed medical doctor with board certification in Physical Medicine & Rehabilitation with specialization in non-invasive pain management.

Safe Harbor for Forward-Looking Statements.

This press release may contain forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 (the "Act"). In Particular, when used, the words "plan," "confident that," "believe," "scheduled," "expect," or "intend to," and similar conditional expressions are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements.

Keith Houser, CEO of BioTech Medics, +1-972-274-5533

CONTACT: Keith Houser, CEO of BioTech Medics, Inc., +1-972-274-5533

Web site: http://www.biotechmedics.com/